Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib
Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib are primarily used in the initial treatment of chronic phase (CP)-chronic myeloid leukemia (CML), as CMLs harbor the BCR-ABL fusion product. An increased number of lymphocytes and large granular lymphocytes (LGLs) have be...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2018-03, Vol.15 (3), p.2935-2938 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2938 |
|---|---|
| container_issue | 3 |
| container_start_page | 2935 |
| container_title | Oncology letters |
| container_volume | 15 |
| creator | Jo, Tatsuro Noguchi, Kazuhiro Hayashi, Shizuka Irie, Sadaharu Hayase, Risa Shioya, Haruna Kaneko, Youhei Horio, Kensuke Taguchi, Jun |
| description | Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib are primarily used in the initial treatment of chronic phase (CP)-chronic myeloid leukemia (CML), as CMLs harbor the BCR-ABL fusion product. An increased number of lymphocytes and large granular lymphocytes (LGLs) have been observed in patients treated with dasatinib, but not other TKIs. The LGLs have been reported to be primarily natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). In the present study, a CP-CML patient who has maintained molecular response 5 for >2.4 years after stopping dasatinib was reported. Memory and effector CTLs and NK cells, were observed after 2.4 years of treatment-free remission, despite the fact that lymphocyte counts are not elevated in the patient. These results suggest that dasatinib may induce cellular immunity, including NK cells and CTLs and this cellular immunity may be maintained for a long period following cessation of dasatinib. The results suggest that this cellular immunity may provide a long-term cure without the need for continued TKI treatment. |
| doi_str_mv | 10.3892/ol.2017.7720 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5778875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A533095374</galeid><sourcerecordid>A533095374</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-416a24cba113633e53728fbf01d8b0314eae98882c2e0eb48acffd119a5db9a63</originalsourceid><addsrcrecordid>eNptkkuLFDEQxxtR3GXdm2cJCOLBHvPoTKcvwrL4ggEveg7V6eqZrHmMSbcwX8FPbdpdhxkxIaRIfvWvSqWq6jmjK6E6_ja6FaesXbUtp4-qS9Z2vGZU8cdHu20uquuc72gZcs2UWj-tLnjXCEk5u6x-bWLY1g7yZMOWePQxHUgciUHnZgeJWO_nYKcDsYEAMbsUgzXEH9BFOxCH83f0FsgeJothIh5smMrKxEeH5o9EwryPISORBMYJUxHPufAxLJEGWOxg-2fVkxFcxuuH_ar69uH919tP9ebLx8-3N5vaSEanumFr4I3pgTGxFgKlaLka-5GyQfVUsAYBO6UUNxwp9o0CM44DYx3Ioe9gLa6qd_e6-7n3OJiSdgKn98l6SAcdwerzm2B3eht_atm2SrWyCLx-EEjxx4x50t7mpWAQMM5Zc0pZx0THm4K-_Ae9i3MK5XmFYo1ouGQn1BYcahvGWOKaRVTfSCFoV964UKv_UGUO5QdMDDjacn7m8OrEYYfgpl2Obl4qn8_BN_egSTHnhOOxGIzqpc90dEu-rV76rOAvTgt4hP92lfgNJUTOqA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014342514</pqid></control><display><type>article</type><title>Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib</title><source>Spandidos Publications Journals</source><source>PMC (PubMed Central)</source><source>EZB Electronic Journals Library</source><creator>Jo, Tatsuro ; Noguchi, Kazuhiro ; Hayashi, Shizuka ; Irie, Sadaharu ; Hayase, Risa ; Shioya, Haruna ; Kaneko, Youhei ; Horio, Kensuke ; Taguchi, Jun</creator><creatorcontrib>Jo, Tatsuro ; Noguchi, Kazuhiro ; Hayashi, Shizuka ; Irie, Sadaharu ; Hayase, Risa ; Shioya, Haruna ; Kaneko, Youhei ; Horio, Kensuke ; Taguchi, Jun</creatorcontrib><description>Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib are primarily used in the initial treatment of chronic phase (CP)-chronic myeloid leukemia (CML), as CMLs harbor the BCR-ABL fusion product. An increased number of lymphocytes and large granular lymphocytes (LGLs) have been observed in patients treated with dasatinib, but not other TKIs. The LGLs have been reported to be primarily natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). In the present study, a CP-CML patient who has maintained molecular response 5 for >2.4 years after stopping dasatinib was reported. Memory and effector CTLs and NK cells, were observed after 2.4 years of treatment-free remission, despite the fact that lymphocyte counts are not elevated in the patient. These results suggest that dasatinib may induce cellular immunity, including NK cells and CTLs and this cellular immunity may be maintained for a long period following cessation of dasatinib. The results suggest that this cellular immunity may provide a long-term cure without the need for continued TKI treatment.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2017.7720</identifier><identifier>PMID: 29435021</identifier><language>eng</language><publisher>Greece: Spandidos Publications</publisher><subject>Bone marrow ; Case 2 ; Cellular immunity ; Chronic myeloid leukemia ; Cytotoxicity ; Dasatinib ; Dosage and administration ; Drug therapy ; Gene expression ; Health aspects ; Immunology ; Kinases ; Leukemia ; Lymphocytes ; Memory ; Oncogenes ; Oncology ; Patient outcomes ; Patients ; Physiological aspects ; Stem cells ; T cell receptors</subject><ispartof>Oncology letters, 2018-03, Vol.15 (3), p.2935-2938</ispartof><rights>COPYRIGHT 2018 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2018</rights><rights>Copyright: © Jo et al. 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-416a24cba113633e53728fbf01d8b0314eae98882c2e0eb48acffd119a5db9a63</citedby><cites>FETCH-LOGICAL-c510t-416a24cba113633e53728fbf01d8b0314eae98882c2e0eb48acffd119a5db9a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778875/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778875/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53770,53772</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29435021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jo, Tatsuro</creatorcontrib><creatorcontrib>Noguchi, Kazuhiro</creatorcontrib><creatorcontrib>Hayashi, Shizuka</creatorcontrib><creatorcontrib>Irie, Sadaharu</creatorcontrib><creatorcontrib>Hayase, Risa</creatorcontrib><creatorcontrib>Shioya, Haruna</creatorcontrib><creatorcontrib>Kaneko, Youhei</creatorcontrib><creatorcontrib>Horio, Kensuke</creatorcontrib><creatorcontrib>Taguchi, Jun</creatorcontrib><title>Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib are primarily used in the initial treatment of chronic phase (CP)-chronic myeloid leukemia (CML), as CMLs harbor the BCR-ABL fusion product. An increased number of lymphocytes and large granular lymphocytes (LGLs) have been observed in patients treated with dasatinib, but not other TKIs. The LGLs have been reported to be primarily natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). In the present study, a CP-CML patient who has maintained molecular response 5 for >2.4 years after stopping dasatinib was reported. Memory and effector CTLs and NK cells, were observed after 2.4 years of treatment-free remission, despite the fact that lymphocyte counts are not elevated in the patient. These results suggest that dasatinib may induce cellular immunity, including NK cells and CTLs and this cellular immunity may be maintained for a long period following cessation of dasatinib. The results suggest that this cellular immunity may provide a long-term cure without the need for continued TKI treatment.</description><subject>Bone marrow</subject><subject>Case 2</subject><subject>Cellular immunity</subject><subject>Chronic myeloid leukemia</subject><subject>Cytotoxicity</subject><subject>Dasatinib</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Gene expression</subject><subject>Health aspects</subject><subject>Immunology</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Lymphocytes</subject><subject>Memory</subject><subject>Oncogenes</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Stem cells</subject><subject>T cell receptors</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkkuLFDEQxxtR3GXdm2cJCOLBHvPoTKcvwrL4ggEveg7V6eqZrHmMSbcwX8FPbdpdhxkxIaRIfvWvSqWq6jmjK6E6_ja6FaesXbUtp4-qS9Z2vGZU8cdHu20uquuc72gZcs2UWj-tLnjXCEk5u6x-bWLY1g7yZMOWePQxHUgciUHnZgeJWO_nYKcDsYEAMbsUgzXEH9BFOxCH83f0FsgeJothIh5smMrKxEeH5o9EwryPISORBMYJUxHPufAxLJEGWOxg-2fVkxFcxuuH_ar69uH919tP9ebLx8-3N5vaSEanumFr4I3pgTGxFgKlaLka-5GyQfVUsAYBO6UUNxwp9o0CM44DYx3Ioe9gLa6qd_e6-7n3OJiSdgKn98l6SAcdwerzm2B3eht_atm2SrWyCLx-EEjxx4x50t7mpWAQMM5Zc0pZx0THm4K-_Ae9i3MK5XmFYo1ouGQn1BYcahvGWOKaRVTfSCFoV964UKv_UGUO5QdMDDjacn7m8OrEYYfgpl2Obl4qn8_BN_egSTHnhOOxGIzqpc90dEu-rV76rOAvTgt4hP92lfgNJUTOqA</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Jo, Tatsuro</creator><creator>Noguchi, Kazuhiro</creator><creator>Hayashi, Shizuka</creator><creator>Irie, Sadaharu</creator><creator>Hayase, Risa</creator><creator>Shioya, Haruna</creator><creator>Kaneko, Youhei</creator><creator>Horio, Kensuke</creator><creator>Taguchi, Jun</creator><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180301</creationdate><title>Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib</title><author>Jo, Tatsuro ; Noguchi, Kazuhiro ; Hayashi, Shizuka ; Irie, Sadaharu ; Hayase, Risa ; Shioya, Haruna ; Kaneko, Youhei ; Horio, Kensuke ; Taguchi, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-416a24cba113633e53728fbf01d8b0314eae98882c2e0eb48acffd119a5db9a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bone marrow</topic><topic>Case 2</topic><topic>Cellular immunity</topic><topic>Chronic myeloid leukemia</topic><topic>Cytotoxicity</topic><topic>Dasatinib</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Gene expression</topic><topic>Health aspects</topic><topic>Immunology</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Lymphocytes</topic><topic>Memory</topic><topic>Oncogenes</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Stem cells</topic><topic>T cell receptors</topic><toplevel>online_resources</toplevel><creatorcontrib>Jo, Tatsuro</creatorcontrib><creatorcontrib>Noguchi, Kazuhiro</creatorcontrib><creatorcontrib>Hayashi, Shizuka</creatorcontrib><creatorcontrib>Irie, Sadaharu</creatorcontrib><creatorcontrib>Hayase, Risa</creatorcontrib><creatorcontrib>Shioya, Haruna</creatorcontrib><creatorcontrib>Kaneko, Youhei</creatorcontrib><creatorcontrib>Horio, Kensuke</creatorcontrib><creatorcontrib>Taguchi, Jun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jo, Tatsuro</au><au>Noguchi, Kazuhiro</au><au>Hayashi, Shizuka</au><au>Irie, Sadaharu</au><au>Hayase, Risa</au><au>Shioya, Haruna</au><au>Kaneko, Youhei</au><au>Horio, Kensuke</au><au>Taguchi, Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>15</volume><issue>3</issue><spage>2935</spage><epage>2938</epage><pages>2935-2938</pages><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Tyrosine kinase inhibitors (TKIs), including imatinib, dasatinib and nilotinib are primarily used in the initial treatment of chronic phase (CP)-chronic myeloid leukemia (CML), as CMLs harbor the BCR-ABL fusion product. An increased number of lymphocytes and large granular lymphocytes (LGLs) have been observed in patients treated with dasatinib, but not other TKIs. The LGLs have been reported to be primarily natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). In the present study, a CP-CML patient who has maintained molecular response 5 for >2.4 years after stopping dasatinib was reported. Memory and effector CTLs and NK cells, were observed after 2.4 years of treatment-free remission, despite the fact that lymphocyte counts are not elevated in the patient. These results suggest that dasatinib may induce cellular immunity, including NK cells and CTLs and this cellular immunity may be maintained for a long period following cessation of dasatinib. The results suggest that this cellular immunity may provide a long-term cure without the need for continued TKI treatment.</abstract><cop>Greece</cop><pub>Spandidos Publications</pub><pmid>29435021</pmid><doi>10.3892/ol.2017.7720</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2018-03, Vol.15 (3), p.2935-2938 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5778875 |
| source | Spandidos Publications Journals; PMC (PubMed Central); EZB Electronic Journals Library |
| subjects | Bone marrow Case 2 Cellular immunity Chronic myeloid leukemia Cytotoxicity Dasatinib Dosage and administration Drug therapy Gene expression Health aspects Immunology Kinases Leukemia Lymphocytes Memory Oncogenes Oncology Patient outcomes Patients Physiological aspects Stem cells T cell receptors |
| title | Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T16%3A28%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-lasting%20memory%20of%20cellular%20immunity%20in%20a%20chronic%20myeloid%20leukemia%20patient%20maintains%20molecular%20response%205%20after%20cessation%20of%20dasatinib&rft.jtitle=Oncology%20letters&rft.au=Jo,%20Tatsuro&rft.date=2018-03-01&rft.volume=15&rft.issue=3&rft.spage=2935&rft.epage=2938&rft.pages=2935-2938&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2017.7720&rft_dat=%3Cgale_pubme%3EA533095374%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2014342514&rft_id=info:pmid/29435021&rft_galeid=A533095374&rfr_iscdi=true |